Levi Garraway is a physician-scientist and global leader in precision oncology, currently serving as Executive Vice President, Head of Global Product Development, and Chief Medical Officer at Roche (since 2019). In this role, he oversees the development of innovative cancer medicines across targeted therapy, immunotherapy, cell and gene therapy, and diagnostics. Dr. Garraway served as faculty at Dana-Farber, Harvard Medical School, and the Broad Institute, where his research helped define the genomic foundations of cancer, including the discovery of key oncogenic drivers in melanoma.
A pioneer of clinical cancer genomics, Dr. Garraway co-founded Foundation Medicine, translating comprehensive tumor genomic profiling into routine clinical care and helping establish precision oncology as a global standard. More than one million patients worldwide have benefited from Foundation Medicine–based testing.
He has served as Senior Vice President of Oncology R&D at Eli Lilly and co-founded Tango Therapeutics. Dr. Garraway has received numerous honors, including the NIH Director’s New Innovator Award, NCI Outstanding Investigator Award, Paul Marks Prize, AACR–Jane Cooke Wright Award, and the Margaret J. Foti Award for Leadership and Extraordinary Achievement in Cancer Research.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership, and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, hono0r, and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
